New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-naïve subgroup, with a manageable safety profile. Results support the ongoing Phase 3 RASolve 301 trial.

09/02/2026, 5:50 PM • GlobeNewswire

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

Revolution Medicines received rapid FDA approval for Rasonque, a novel pancreatic cancer treatment using a RAS inhibitor mechanism. The drug demonstrated strong Phase 3 trial results and analysts project peak annual sales of $11.5 billion. The stock has surged 178% year-to-date, with potential for further expansion into other cancer indications affecting 30% of solid tumors.

08/28/2026, 7:07 AM • The Motley Fool

Onco360® Has Been Selected as a National Pharmacy Partner for RASONQUE™ (daraxonrasib)

Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Revolution Medicines for the launch of RASONQUE (daraxonrasib), a RAS GTPase inhibitor for metastatic pancreatic adenocarcinoma. The drug showed significant clinical benefits in the phase 3 RASolute-302 trial, with median PFS of 7.3 months and OS of 13.2 months in RAS G12 mutation patients compared to 3.5 months and 6.6 months respectively for chemotherapy.

08/26/2026, 6:17 PM • GlobeNewswire

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

The FDA has approved RASONQUE (daraxonrasib), developed by Revolution Medicines, as the first targeted RAS inhibitor for treating metastatic pancreatic adenocarcinoma in patients who have received prior systemic therapy or are not candidates for multiagent chemotherapy. In the Phase 3 RASolute 302 trial, RASONQUE reduced the risk of death by 60% compared to chemotherapy, with median overall survival of 13.2 months versus 6.7 months, and demonstrated manageable safety with improved quality of life measures.

08/26/2026, 12:59 PM • GlobeNewswire

ERASCA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERAS

A securities class action lawsuit has been filed against Erasca, Inc. and its executives for allegedly making false and misleading statements about its lead oncology drug candidate ERAS-0015. The company is accused of improperly comparing its drug to a competitor's candidate and failing to disclose patent and trade secret disputes. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 must act by August 10, 2026 to serve as lead plaintiff.

08/08/2026, 4:51 PM • GlobeNewswire

ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights

A class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims the preclinical data was based on improper comparisons and lacked reasonable basis. Following a patent infringement allegation from Revolution Medicines disclosed on April 28, 2026, Erasca's stock price declined approximately 48% from $19.15 to $9.90 per share. Investors have until August 10, 2026 to apply as lead plaintiff.

08/07/2026, 3:47 PM • GlobeNewswire

ERAS 3-DAY DEADLINE ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– Hagens Berman

Hagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials, triggering a $2.8 billion market capitalization loss. Investors with substantial losses can serve as lead plaintiffs with an August 10, 2026 deadline.

08/07/2026, 3:44 PM • GlobeNewswire

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline

Hagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials. These disclosures in late April 2026 triggered a sharp stock decline, erasing over $2.8 billion in market capitalization. The lead plaintiff deadline is August 10, 2026.

08/05/2026, 10:27 PM • GlobeNewswire

MONDAY DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - ERAS

Robbins Geller Rudman & Dowd LLP is seeking a lead plaintiff for a securities class action lawsuit against Erasca, Inc. The lawsuit alleges that Erasca made false and misleading statements regarding its ERAS-0015 drug candidate, including improper comparisons to competitor Revolution Medicines' technology and undisclosed patent infringement risks. Following disclosure of a patent infringement letter and adverse clinical trial data on April 27, 2026, Erasca's stock price fell approximately 59% combined. The deadline to apply as lead plaintiff is August 10, 2026.

08/04/2026, 7:55 AM • GlobeNewswire

ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights

A class action lawsuit has been filed against Erasca, Inc. alleging the company made false statements about its ERAS-0015 drug candidate based on improper comparisons and lacking reasonable basis. Following a patent infringement allegation from Revolution Medicines disclosed on April 28, 2026, Erasca's stock price plummeted 48% from $19.15 to $9.90 per share. Investors have until August 10, 2026 to apply as lead plaintiff.

08/03/2026, 6:27 PM • GlobeNewswire

Robbins LLP Reminds Erasca, Inc. Investors of the Pending Lead Plaintiff Deadline in the Securities Fraud Class Action; Contact the Firm to Learn About Your Rights

A securities fraud class action has been filed against Erasca, Inc. (NASDAQ: ERAS) for allegedly failing to disclose risks related to patent and trade secret violations. The lawsuit stems from Erasca's ERAS-0015 drug candidate, which Revolution Medicines claims infringes its patent and involves misappropriated trade secrets. The stock dropped from $21.49 to $19.15 per share following the disclosure on April 27, 2026. Investors have until August 10, 2026 to submit lead plaintiff papers.

07/31/2026, 10:28 AM • GlobeNewswire

ERAS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - August 10, 2026 Deadline

Erasca, Inc. faces a securities class action lawsuit alleging that the company and its executives made false statements about its lead drug candidate ERAS-0015. The lawsuit claims Erasca's preclinical data involved improper comparisons and failed to disclose patent infringement risks from Revolution Medicines. Following disclosure of a patent assertion letter and adverse clinical trial data on April 27, 2026, Erasca's stock fell approximately 59% over two trading days. Investors with substantial losses can seek lead plaintiff status by August 10, 2026.

07/28/2026, 7:45 AM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors that a Class Action Lawsuit Has Been Filed Against Erasca and Encourages Investors to Contact the Firm Before August 10th

A class action lawsuit has been filed against Erasca, Inc. alleging the company made false statements about its ERAS-0015 drug candidate based on improper comparisons and lacking reasonable basis for positive claims. The lawsuit was triggered after Revolution Medicines alleged patent infringement and trade secret misappropriation on April 28, 2026, causing Erasca's stock to plunge 48% from $19.15 to $9.90 per share. Investors who purchased shares between January 14, 2025 and April 26, 2026 have until August 10, 2026 to apply as lead plaintiff.

07/23/2026, 5:53 PM • GlobeNewswire

Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight

The molecular glues market is experiencing significant growth with over 80 active players developing 90+ pipeline candidates. Key companies including Revolution Medicines, Gluetacs Therapeutics, Captor Therapeutics, and others are advancing promising molecular glue degraders across oncology, immunology, and neurodegenerative diseases. Recent developments include FDA Breakthrough Therapy Designation for Daraxonrasib and multiple clinical trial initiations, positioning molecular glues as a promising therapeutic strategy for previously undruggable proteins.

07/23/2026, 1:00 PM • GlobeNewswire

This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It

Revolution Medicines, a pre-revenue biotech company developing targeted cancer treatments to replace chemotherapy, has surged 125% in 2026. The company's flagship drug Daraxonrasib received FDA Breakthrough Therapy designation and is undergoing accelerated review by the EMA. Billionaire Stanley Druckenmiller's Duquesne Family Office purchased 316,000 shares worth $30.6 million in Q1 2026, now valued at $56.6 million, signaling confidence in the company's potential despite its speculative nature.

07/17/2026, 8:30 AM • The Motley Fool